New Horizon Health

The company's product portfolio is central to its business model, which generates revenue through the sale of these screening tests via multiple channels, including hospitals, e-commerce platforms, insurance companies, and health checkup centers. Its flagship product, ColoClear, is a non-invasive, multi-target FIT-DNA test for colorectal cancer, notable for being the first of its kind approved by China's National Medical Products Administration (NMPA). Another key product is the Pupu Tube, a self-administered fecal immunochemical test (FIT) designed for the preliminary screening of colorectal cancer. The portfolio also includes UU Tube, a stool-based test for detecting H. pylori, a primary causative agent for gastric cancer, and CerviClear, a urine-based home-use test for cervical cancer screening. New Horizon Health holds global rights to all its marketed and pipeline products.

The company targets the vast population in China at risk for or recommended for cancer screening. For instance, ColoClear is aimed at the 120 million people considered high-risk for colorectal cancer, while Pupu Tube targets a broader market of over 600 million individuals recommended for screening. The business strategy appears to be focused on capturing the significant unmet need for accessible cancer screening, driven by national health initiatives like Healthy China 2030. While the company has demonstrated substantial revenue growth, it also faced challenges, including allegations of financial data inflation in 2023, which the company denied. This led to a delay in publishing its 2023 annual report, a trading halt, and an independent investigation. In late 2023, CEO Zhu Yeqing stepped down for health reasons, with the board noting differences in management style.